# Exponent Inc: financial statements, quarterly

EXPO · Nasdaq · CIK 851520 · [Industrials](/sectors/industrials.md) · fiscal year ends Jan 1

Pages: [Overview](/companies/expo.md) · [Financials](/companies/expo/financials.md) · [Filings](/companies/expo/filings.md) · [Insiders](/companies/expo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/expo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-29) | Q4 FY2023 (2023-12-29) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q4 FY2024 (2025-01-03) | Q1 FY2025 (2025-04-04) | Q2 FY2025 (2025-07-04) | Q3 FY2025 (2025-10-03) | Q4 FY2025 (2026-01-02) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [133](/filings/0000950170-24-119886.md) | [123 d](/filings/0001193125-26-082508.md) | [145](/filings/0000950170-25-067987.md) | [141](/filings/0000950170-25-105799.md) | [136](/filings/0001193125-25-272273.md) | [137 d](/filings/0001193125-26-082508.md) | [146](/filings/0001193125-26-214572.md) | [142](/filings/0001193125-26-340211.md) | [147](/filings/0001193125-25-272273.md) | [147 d](/filings/0001193125-26-082508.md) | [166](/filings/0001193125-26-214572.md) | [172](/filings/0001193125-26-340211.md) |
| Operating income | $m | [33.9](/filings/0000950170-24-119886.md) | [18.4 d](/filings/0001193125-26-082508.md) | [30.7](/filings/0000950170-25-067987.md) | [35.7](/filings/0000950170-25-105799.md) | [25.8](/filings/0001193125-25-272273.md) | [27.3 d](/filings/0001193125-26-082508.md) | [44.4](/filings/0001193125-26-214572.md) | [17.2](/filings/0001193125-26-340211.md) | [29.0](/filings/0001193125-25-272273.md) | [29.1 d](/filings/0001193125-26-082508.md) | [41.4](/filings/0001193125-26-214572.md) | [28.0](/filings/0001193125-26-340211.md) |
| Income tax | $m | [9.5](/filings/0000950170-24-119886.md) | [9.2 d](/filings/0001193125-26-082508.md) | [10.3](/filings/0000950170-25-067987.md) | [10.5](/filings/0000950170-25-105799.md) | [9.9](/filings/0001193125-25-272273.md) | [7.7 d](/filings/0001193125-26-082508.md) | [11.1](/filings/0001193125-26-214572.md) | [10.3](/filings/0001193125-26-340211.md) | [10.6](/filings/0001193125-25-272273.md) | [9.3 d](/filings/0001193125-26-082508.md) | [12.8](/filings/0001193125-26-214572.md) | [11.4](/filings/0001193125-26-340211.md) |
| Net income | $m | [24.5](/filings/0000950170-24-119886.md) | [20.9 d](/filings/0001193125-26-082508.md) | [30.1](/filings/0000950170-25-105799.md) | [29.2](/filings/0000950170-25-105799.md) | [26.0](/filings/0001193125-25-272273.md) | [23.6 d](/filings/0001193125-26-082508.md) | [26.7](/filings/0001193125-26-340211.md) | [26.6](/filings/0001193125-26-340211.md) | [28.0](/filings/0001193125-25-272273.md) | [24.8 d](/filings/0001193125-26-082508.md) | [29.6](/filings/0001193125-26-340211.md) | [29.4](/filings/0001193125-26-340211.md) |
| Diluted EPS | $ per share | [0.48](/filings/0000950170-24-119886.md) | not reported | [0.59](/filings/0000950170-25-067987.md) | [0.57](/filings/0000950170-25-105799.md) | [0.50](/filings/0001193125-25-272273.md) | not reported | [0.52](/filings/0001193125-26-214572.md) | [0.52](/filings/0001193125-26-340211.md) | [0.55](/filings/0001193125-25-272273.md) | not reported | [0.59](/filings/0001193125-26-214572.md) | [0.60](/filings/0001193125-26-340211.md) |
| Basic EPS | $ per share | [0.48](/filings/0000950170-24-119886.md) | not reported | [0.59](/filings/0000950170-25-067987.md) | [0.57](/filings/0000950170-25-105799.md) | [0.51](/filings/0001193125-25-272273.md) | not reported | [0.52](/filings/0001193125-26-214572.md) | [0.52](/filings/0001193125-26-340211.md) | [0.55](/filings/0001193125-25-272273.md) | not reported | [0.59](/filings/0001193125-26-214572.md) | [0.60](/filings/0001193125-26-340211.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-29) | FY2023 (2023-12-29) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | FY2024 (2025-01-03) | Q1 FY2025 (2025-04-04) | Q2 FY2025 (2025-07-04) | Q3 FY2025 (2025-10-03) | FY2025 (2026-01-02) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [137](/filings/0000950170-23-058876.md) | [187](/filings/0000950170-25-030001.md) | [169](/filings/0000950170-24-052966.md) | [203](/filings/0000950170-24-089943.md) | [220](/filings/0000950170-24-119886.md) | [259](/filings/0001193125-26-082508.md) | [245](/filings/0000950170-25-067987.md) | [232](/filings/0000950170-25-105799.md) | [207](/filings/0001193125-25-272273.md) | [222](/filings/0001193125-26-340211.md) | [119](/filings/0001193125-26-214572.md) | [66.6](/filings/0001193125-26-340211.md) |
| Current assets | $m | [343](/filings/0000950170-23-058876.md) | [380](/filings/0000950170-25-030001.md) | [352](/filings/0000950170-24-052966.md) | [391](/filings/0000950170-24-089943.md) | [413](/filings/0000950170-24-119886.md) | [447](/filings/0001193125-26-082508.md) | [433](/filings/0000950170-25-067987.md) | [426](/filings/0000950170-25-105799.md) | [417](/filings/0001193125-25-272273.md) | [428](/filings/0001193125-26-340211.md) | [341](/filings/0001193125-26-214572.md) | [312](/filings/0001193125-26-340211.md) |
| Total assets | $m | [602](/filings/0000950170-23-058876.md) | [647](/filings/0000950170-25-030001.md) | [629](/filings/0000950170-24-052966.md) | [709](/filings/0000950170-24-089943.md) | [744](/filings/0000950170-24-119886.md) | [777](/filings/0001193125-26-082508.md) | [763](/filings/0000950170-25-067987.md) | [759](/filings/0000950170-25-105799.md) | [761](/filings/0001193125-25-272273.md) | [778](/filings/0001193125-26-340211.md) | [687](/filings/0001193125-26-214572.md) | [653](/filings/0001193125-26-340211.md) |
| Current liabilities | $m | [130](/filings/0000950170-23-058876.md) | [162](/filings/0000950170-25-030001.md) | [114](/filings/0000950170-24-052966.md) | [132](/filings/0000950170-24-089943.md) | [138](/filings/0000950170-24-119886.md) | [163](/filings/0001193125-26-082508.md) | [130](/filings/0000950170-25-067987.md) | [135](/filings/0000950170-25-105799.md) | [155](/filings/0001193125-25-272273.md) | [178](/filings/0001193125-26-340211.md) | [142](/filings/0001193125-26-214572.md) | [158](/filings/0001193125-26-340211.md) |
| Total liabilities | $m | [249](/filings/0000950170-23-058876.md) | [291](/filings/0000950170-25-030001.md) | [255](/filings/0000950170-24-052966.md) | [316](/filings/0000950170-24-089943.md) | [334](/filings/0000950170-24-119886.md) | [356](/filings/0001193125-26-082508.md) | [322](/filings/0000950170-25-067987.md) | [332](/filings/0000950170-25-105799.md) | [359](/filings/0001193125-25-272273.md) | [387](/filings/0001193125-26-340211.md) | [349](/filings/0001193125-26-214572.md) | [364](/filings/0001193125-26-340211.md) |
| Shareholders' equity | $m | [354](/filings/0000950170-24-119886.md) | [356](/filings/0001193125-26-082508.md) | [374](/filings/0000950170-25-105799.md) | [393](/filings/0001193125-25-272273.md) | [410](/filings/0001193125-25-272273.md) | [421](/filings/0001193125-26-340211.md) | [441](/filings/0001193125-26-340211.md) | [428](/filings/0001193125-26-340211.md) | [403](/filings/0001193125-25-272273.md) | [390](/filings/0001193125-26-340211.md) | [338](/filings/0001193125-26-340211.md) | [289](/filings/0001193125-26-340211.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-29) | Q4 FY2023 (2023-12-29) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q4 FY2024 (2025-01-03) | Q1 FY2025 (2025-04-04) | Q2 FY2025 (2025-07-04) | Q3 FY2025 (2025-10-03) | Q4 FY2025 (2026-01-02) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [22.2 d](/filings/0000950170-24-119886.md) | [71.3 d](/filings/0001193125-26-082508.md) | [10.4](/filings/0000950170-25-067987.md) | [48.3 d](/filings/0000950170-25-105799.md) | [29.7 d](/filings/0001193125-25-272273.md) | [56.1 d](/filings/0001193125-26-082508.md) | [7.3](/filings/0001193125-26-214572.md) | [36.2 d](/filings/0001193125-26-340211.md) | [32.7 d](/filings/0001193125-25-272273.md) | [55.6 d](/filings/0001193125-26-082508.md) | [(1.0)](/filings/0001193125-26-214572.md) | [30.9 d](/filings/0001193125-26-340211.md) |
| Capital expenditure | $m | [3.3 d](/filings/0000950170-24-119886.md) | [1.9 d](/filings/0001193125-26-082508.md) | [1.5](/filings/0000950170-25-067987.md) | [1.1 d](/filings/0000950170-25-105799.md) | [1.7 d](/filings/0001193125-25-272273.md) | [2.6 d](/filings/0001193125-26-082508.md) | [1.8](/filings/0001193125-26-214572.md) | [2.3 d](/filings/0001193125-26-340211.md) | [2.7 d](/filings/0001193125-25-272273.md) | [2.7 d](/filings/0001193125-26-082508.md) | [2.5](/filings/0001193125-26-214572.md) | [1.8 d](/filings/0001193125-26-340211.md) |
| Dividends paid | $m | [13.2](/filings/0000950170-25-030001.md) | [13.1](/filings/0000950170-25-030001.md) | [14.2](/filings/0001193125-26-082508.md) | [14.2](/filings/0001193125-26-082508.md) | [14.2](/filings/0001193125-26-082508.md) | [14.2](/filings/0001193125-26-082508.md) | [15.2](/filings/0001193125-26-082508.md) | [15.2](/filings/0001193125-26-082508.md) | [15.1](/filings/0001193125-26-082508.md) | [14.9](/filings/0001193125-26-082508.md) | [16.6](/filings/0001193125-26-214572.md) | [14.8 d](/filings/0001193125-26-340211.md) |
| Share repurchases | $m | not reported | [7.2 d](/filings/0001193125-26-082508.md) | [5.5](/filings/0000950170-25-067987.md) | [0.2 d](/filings/0000950170-25-105799.md) | [(0.0) d](/filings/0001193125-25-272273.md) | [0.0 d](/filings/0001193125-26-082508.md) | not reported | not reported | [40.0 d](/filings/0001193125-25-272273.md) | [24.4 d](/filings/0001193125-26-082508.md) | [78.8](/filings/0001193125-26-214572.md) | [67.4 d](/filings/0001193125-26-340211.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock, us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-29) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q1 FY2025 (2025-04-04) | Q2 FY2025 (2025-07-04) | Q3 FY2025 (2025-10-03) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [52.0](/filings/0000950170-23-058876.md) | [51.7](/filings/0000950170-24-052966.md) | [51.7](/filings/0000950170-24-089943.md) | [51.6](/filings/0000950170-24-119886.md) | [51.4](/filings/0000950170-25-067987.md) | [51.5](/filings/0000950170-25-105799.md) | [51.6](/filings/0001193125-25-272273.md) | [51.7](/filings/0001193125-26-214572.md) | [51.5](/filings/0001193125-26-340211.md) | [51.2](/filings/0001193125-25-272273.md) | [50.1](/filings/0001193125-26-214572.md) | [49.0](/filings/0001193125-26-340211.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 47,546,084 at 2026-07-31, from the cover of the [10-Q filed 2026-08-07](/filings/0001193125-26-340211.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.